Bayer vs Grifols (BAYN.DE vs GRF)
Bayer (BAYN.DE) vs Grifols (GRF) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.
Bayer (BAYN.DE) and Grifols (GRF) compete in healthcare and pharma. Here are Bayer and Grifols side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Bayer or Grifols.
Bayer vs Grifols: the figures
| Figure | Bayer | Grifols |
|---|---|---|
| Share price | €54.24 (November 4, 2026) | €11.22 (November 4, 2026) |
| Market cap | €53.3 billion | €7.6 billion |
| P/E (TTM) | N/A | 15.8x |
| Forward P/E | 11.2x | 10.1x |
| Revenue growth (quarter) | +1.2% | +9.4% |
| Net margin (TTM) | -3.8% | 6.4% |
| Net debt / EBITDA | 3.3x | 5.0x |
| Dividend yield | 0.22% | 0.73% |
| Beta | 0.81 | N/A |
Bayer and Grifols figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Bayer or Grifols figure is not available, and we never estimate it.
3 key differences between Bayer and Grifols
- Profitability: for every 100 of sales, Grifols keeps 6.4 as net profit and Bayer keeps -3.8.
- Size: Bayer is worth €53.3 billion on the stock market, about 7.0 times Grifols (€7.6 billion).
- Debt: Grifols owes 5.0x its annual operating profit (EBITDA), while Bayer owes 3.3x its EBITDA.
Bayer or Grifols: which fits your profile
- If you want growth: Grifols is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
- If you want income (dividends): Grifols pays the higher dividend relative to its price.
- If you prefer caution: Bayer has less debt relative to its profit, which usually gives more room in a bad year.
Neither Bayer nor Grifols wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.
How Bayer and Grifols make money
Bayer (BAYN.DE)
Bayer reports three divisions: Crop Science, its largest, selling seeds (Dekalb) and crop protection to farmers; Pharmaceuticals, with prescription drugs such as Xarelto, Eylea and Nubeqa; and Consumer Health, with over-the-counter brands like Aspirin, Bepanthen and Claritin. It sells worldwide, with North America and Europe as its main markets. Full Bayer analysis.
Grifols (GRF)
Grifols collects plasma from donors at its network of centers, mostly in the US, and turns it into medicines. Its Biopharma division, the largest, sells immunoglobulins, albumin and other plasma proteins to hospitals; Diagnostic provides blood-screening tests for blood banks and labs; and Bio Supplies sells biological materials. Full Grifols analysis.
Frequently asked questions: Bayer vs Grifols
Is Bayer or Grifols the better stock?
Choosing between Bayer and Grifols depends on what you are looking for. Grifols is growing faster right now. Fintols does not tell you whether to buy Bayer or Grifols: it shows you the differences so you can decide.
Which pays a higher dividend, Bayer or Grifols?
As of November 4, 2026, Grifols yields 0.73% and Bayer yields 0.22%. Also check how much of their profit Bayer and Grifols pay out: if it is more than they earn, it cannot last.
Can I own both Bayer and Grifols?
Yes. Many people spread their money across several companies, such as Bayer and Grifols, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Bayer or Grifols.
More comparisons with Bayer or Grifols
More companies like Bayer and Grifols: healthcare and pharma stocks. Educational content about Bayer and Grifols, not investment advice.